Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Signal recognition particle 9 kDa protein (SRP9)
- Target
- SRP9
- Molecular classification
- Other (component of the signal recognition particle complex; small ribonucleoprotein), Ribonucleoprotein complex member
01
Overview
Signal recognition particle 9 kDa protein (SRP9) is a small, conserved protein that functions as a core structural subunit of the signal recognition particle (SRP) complex, a ribonucleoprotein complex responsible for the cotranslational targeting and translocation of secretory and membrane proteins to the endoplasmic reticulum in eukaryotic cells. SRP9 forms a heterodimer with SRP14, binding to the Alu domain of SRP RNA, and is essential for the elongation arrest function of the SRP, helping to pause translation until the ribosome-mRNA-polypeptide complex can be properly engaged with the ER membrane translocon. Genetic studies have associated variation in SRP9 with susceptibility to motor neuritis, although its direct involvement in disease remains unclear. SRP9 plays an indirect but essential role in protein targeting fidelity and efficiency, with no evidence for direct targeting by therapeutic agents.
- Other names
- SRP9ALURBPSignal recognition particle 9 kDaSignal recognition particle 9kDSignal recognition particle 9kDa
02
Mechanism of action
Not applicable—SRP9 is not a drug target and does not itself have mechanisms of action for drugs.
03
Biological functions
Cotranslational protein targeting to the endoplasmic reticulum (ER)RNA bindingSignal recognition particle bindingRegulation of protein translocation (via the elongation arrest domain with SRP14)
04
Disease associations
Motor neuritis (based on genetic association; no direct indication as a primary pathogenic driver)Other (currently, SRP9 is not a major established disease gene; research is ongoing)
05
Safety considerations
None specific or reported. As SRP9 is not a therapeutic target or biomarker, safety/tolerability issues related to modulation are not documented
06
Interacting drugs
None known
07
Biomarkers
None currently established for SRP9 specifically for patient selection or monitoring treatment response
Beyond the preview
Go deeper on Signal recognition particle 9 kDa protein (SRP9).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Signal recognition particle 9 kDa protein (SRP9).